1|Page
CJE Benchmark Exam Complete Questions &
Answers | Verified Solutions 2026/2027
Comprehensive Clinical Judgment Exam Study Guide
Exam (elaborations)
CJE BENCHMARK EXAM
Complete Questions and Verified Answers with Detailed Rationales
2026/2027 | Already Graded A+
*Course: NR341 / NURS 3251 / Clinical Judgment & Decision Making*
TABLE OF CONTENTS
Section Topic Area Questions
Section 1 Pharmacology & Medication Administration 1-35
Section 2 Respiratory Disorders & Infectious Disease 36-60
Section 3 Cardiovascular & Hemodynamic Management 61-80
Section 4 Neurological & Critical Care 81-95
Section 5 Renal, Fluids & Electrolytes 96-110
,2|Page
Section Topic Area Questions
Section 6 Fundamentals & Basic Care 111-125
Section 7 Clinical Judgment & Prioritization 126-140
About This Study Guide
This comprehensive study guide contains 140 practice questions with
detailed rationales designed to simulate the CJE (Clinical Judgment
Exam) Benchmark format for the 2026-2027 testing cycle. Each
question includes the correct answer, a detailed evidence-based
rationale, and clinical pearls to reinforce understanding of nursing
clinical judgment, pharmacology, and patient management across
healthcare settings.
Key Features:
• ✓ 140+ exam-style questions covering all major clinical areas
• ✓ Verified correct answers with detailed rationales
• ✓ Aligned with NCSBN Clinical Judgment Measurement Model
(NCJMM)
• ✓ Focus on recognizing cues, analyzing data, prioritizing
hypotheses, and evaluating outcomes
• ✓ Includes latest clinical guidelines and treatment protocols
• ✓ Ideal for nursing students preparing for benchmark exams and
NCLEX
,3|Page
SECTION 1: PHARMACOLOGY & MEDICATION
ADMINISTRATION (Questions 1-35)
Question 1
A patient is receiving t-PA (Alteplase) for an acute ischemic stroke.
Which assessment finding is most concerning during the infusion?
A. Mild headache
B. Blood pressure 150/88 mmHg
C. Sudden severe headache, nausea, and neurological deterioration
D. Heart rate 88 bpm
Answer: C. Sudden severe headache, nausea, and neurological
deterioration
Rationale: t-PA (Alteplase) is a thrombolytic agent used to lyse thrombi
in coronary arteries, pulmonary emboli, DVT, and thrombi causing
ischemic stroke. Sudden severe headache, nausea/vomiting, and
worsening neurological status during or after t-PA administration
suggest intracranial hemorrhage, a life-threatening complication. The
infusion should be stopped immediately, emergency CT obtained, and
provider notified.
Clinical Pearl: t-PA reduces neurological sequelae in ischemic stroke
but carries significant bleeding risk. Monitor for any neurological
changes closely.
Question 2
, 4|Page
A patient with ventricular fibrillation is receiving amiodarone. What is
the primary mechanism of action of this medication?
A. Sodium channel blocker
B. Beta-adrenergic blocker
C. Potassium channel blocker (Class III antiarrhythmic)
D. Calcium channel blocker
Answer: C. Potassium channel blocker (Class III antiarrhythmic)
Rationale: Amiodarone (Cordarone) is a Class III antiarrhythmic agent
that works primarily as a potassium channel blocker, prolonging
repolarization and the refractory period. It is used for ventricular
fibrillation, unstable ventricular tachycardia, and supraventricular
tachycardias. It is incompatible with heparin, may be given as PO
maintenance, and requires monitoring for respiratory complications
including pulmonary toxicity and ARDS.
Clinical Pearl: Amiodarone has a long half-life and can accumulate in
tissues; monitor for pulmonary toxicity, thyroid dysfunction, and corneal
microdeposits.
Question 3
A patient with hypertension and angina is prescribed amlodipine. Which
statement best describes the mechanism of action of this medication?
A. Beta-blocker that decreases heart rate and contractility
B. Calcium channel blocker that causes vasodilation and decreases BP
C. ACE inhibitor that prevents angiotensin conversion
D. Thiazide diuretic that promotes fluid excretion
Answer: B. Calcium channel blocker that causes vasodilation and
decreases BP
CJE Benchmark Exam Complete Questions &
Answers | Verified Solutions 2026/2027
Comprehensive Clinical Judgment Exam Study Guide
Exam (elaborations)
CJE BENCHMARK EXAM
Complete Questions and Verified Answers with Detailed Rationales
2026/2027 | Already Graded A+
*Course: NR341 / NURS 3251 / Clinical Judgment & Decision Making*
TABLE OF CONTENTS
Section Topic Area Questions
Section 1 Pharmacology & Medication Administration 1-35
Section 2 Respiratory Disorders & Infectious Disease 36-60
Section 3 Cardiovascular & Hemodynamic Management 61-80
Section 4 Neurological & Critical Care 81-95
Section 5 Renal, Fluids & Electrolytes 96-110
,2|Page
Section Topic Area Questions
Section 6 Fundamentals & Basic Care 111-125
Section 7 Clinical Judgment & Prioritization 126-140
About This Study Guide
This comprehensive study guide contains 140 practice questions with
detailed rationales designed to simulate the CJE (Clinical Judgment
Exam) Benchmark format for the 2026-2027 testing cycle. Each
question includes the correct answer, a detailed evidence-based
rationale, and clinical pearls to reinforce understanding of nursing
clinical judgment, pharmacology, and patient management across
healthcare settings.
Key Features:
• ✓ 140+ exam-style questions covering all major clinical areas
• ✓ Verified correct answers with detailed rationales
• ✓ Aligned with NCSBN Clinical Judgment Measurement Model
(NCJMM)
• ✓ Focus on recognizing cues, analyzing data, prioritizing
hypotheses, and evaluating outcomes
• ✓ Includes latest clinical guidelines and treatment protocols
• ✓ Ideal for nursing students preparing for benchmark exams and
NCLEX
,3|Page
SECTION 1: PHARMACOLOGY & MEDICATION
ADMINISTRATION (Questions 1-35)
Question 1
A patient is receiving t-PA (Alteplase) for an acute ischemic stroke.
Which assessment finding is most concerning during the infusion?
A. Mild headache
B. Blood pressure 150/88 mmHg
C. Sudden severe headache, nausea, and neurological deterioration
D. Heart rate 88 bpm
Answer: C. Sudden severe headache, nausea, and neurological
deterioration
Rationale: t-PA (Alteplase) is a thrombolytic agent used to lyse thrombi
in coronary arteries, pulmonary emboli, DVT, and thrombi causing
ischemic stroke. Sudden severe headache, nausea/vomiting, and
worsening neurological status during or after t-PA administration
suggest intracranial hemorrhage, a life-threatening complication. The
infusion should be stopped immediately, emergency CT obtained, and
provider notified.
Clinical Pearl: t-PA reduces neurological sequelae in ischemic stroke
but carries significant bleeding risk. Monitor for any neurological
changes closely.
Question 2
, 4|Page
A patient with ventricular fibrillation is receiving amiodarone. What is
the primary mechanism of action of this medication?
A. Sodium channel blocker
B. Beta-adrenergic blocker
C. Potassium channel blocker (Class III antiarrhythmic)
D. Calcium channel blocker
Answer: C. Potassium channel blocker (Class III antiarrhythmic)
Rationale: Amiodarone (Cordarone) is a Class III antiarrhythmic agent
that works primarily as a potassium channel blocker, prolonging
repolarization and the refractory period. It is used for ventricular
fibrillation, unstable ventricular tachycardia, and supraventricular
tachycardias. It is incompatible with heparin, may be given as PO
maintenance, and requires monitoring for respiratory complications
including pulmonary toxicity and ARDS.
Clinical Pearl: Amiodarone has a long half-life and can accumulate in
tissues; monitor for pulmonary toxicity, thyroid dysfunction, and corneal
microdeposits.
Question 3
A patient with hypertension and angina is prescribed amlodipine. Which
statement best describes the mechanism of action of this medication?
A. Beta-blocker that decreases heart rate and contractility
B. Calcium channel blocker that causes vasodilation and decreases BP
C. ACE inhibitor that prevents angiotensin conversion
D. Thiazide diuretic that promotes fluid excretion
Answer: B. Calcium channel blocker that causes vasodilation and
decreases BP
